Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET

About this update from Galectin Therapeutics Inc.

[{"type":"image","alt":"Galectin Therapeutics Inc.","displaySize":"","headline":null,"caption":"Galectin Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":267,"height":65,"url":"https://media.zenfs.com/en/globenewswire.com/a11c82d809909171dee0b6a5e015c96b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fDKup_DxRvH1q911Cik6yw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a11c82d809909171dee0b6a5e015c96b","width":267,"height":65}},"lazy":false},{"type":"text","content":"NORCROSS, Ga., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, March 10, 2026 at 12:00 PM ET. To register, click here.","length":349,"tagName":"p"},{"type":"text","content":"The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:","length":193,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell Biology and Physiology, & Director of Terance Kahn Liver Research Program at Indiana University School of Medicine; and","length":227,"tagName":"p"}]},{"val":[{"type":"text","content":"Naim Alkhouri, MD, FAASLD, DABOM, Chief Academic Officer at Summit Clinical Research San Antonio, TX and the Director of the Steatotic Liver Program at North Shore Gastroenterology in Cleveland, OH","length":197,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":424,"olType":false},{"type":"text","content":"The event will highlight updated results from Galectin's NAVIGATE Phase 3 clinical trial evaluating belapectin for the treatment of MASH cirrhosis and portal hypertension. These results reinforce and extend previously reported findings supporting the antifibrotic and disease-modifying potential of belapectin. Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of MASH and fibrosis. With no approved therapies to prevent or treat varices in MASH cirrhosis, belapectin m...

More updates from Galectin Therapeutics Inc.